Cyclopharm Limited

Building a profitable and growing market leader in nuclear medical imaging

Investor Presentation

James McBrayer, CEO

7 October2015

Contents

- 10 Fast Facts
- Vision and company description
- Company History
- Cyclopharm's market leading products
- Growth opportunities and KPI's
- Summary and Outlook
- Appendix: FY 2014 & H1 2015 Financial Results

CYC's 10 FAST FACTS

cyclopharm
Nuclear Medicine

1. Technegas is a well established proprietary world leader in functional lung ventilation imaging technology with major revenues generated by single patient consumables
2. Partnering with DraxImage to leverage significant growth opportunities in the USA for the globally accepted indication for Pulmonary Embolism (PE)
3. Chronic Obstructive Pulmonary Disease (COPD) and Asthma represents a tremendous opportunity for substantial growth world wide
4. Ultralute, a new innovative technology with global application, will be launched late 2015
5. The Ultralute technology represents a platform for additional product development
6. Stable management and workforce

A Rare Australian Biotech that is:

7. Profitable
8. Generating cash with near term capital management opportunities under consideration
9. Net cash on the balance sheet
10. Set to leverage tangible growth opportunities

Vision and strategy

- CYC has clear strategy to leverage our position as a leading player in the global nuclear medicine imaging market by expanding the use of our proprietary products and introduce new innovative technology.
- Leverage core strengths and well developed expertise in lung health management.
- Having developed a leading suite of products CYC is now focussed on driving sales in established and new markets, gaining FDA approval in the USA and expanding product indications to significantly larger applications such as COPD
- CYC's primary focus is to increase awareness and acceptance amongst referring clinicians to drive sales. Strong progress is being made.
- FY14 was a "year of records": $12.1m sales; $4.1m NPAT (Including $2.65m mediation proceeds, and $4.5m operating cash flow ($2.2M from Technegas)
- CYC is profitable, with positive cash flow and net cash on the balance sheet. Well placed to accelerate corporate development and capital management to drive shareholder value.

Our History

cyclopharm
Nuclear Medicine

1984
Technegas discovered & commercialisation trading as Tetley Medical

1992
European markets established

2000
Vita Life Sciences acquires Tetley Medical

2001
USFDA program initiated for Technegas

2007
Technegas Plus generator launched

2013
Ultralute technology established and commercialisation begins

1985 | **1990** | **1995** | **2000** | **2005** | **2010** | **2015**

1988
Technegas enters European market

1996
Technegas registered in the EU as a drug

2003
Canadian regulatory approval attained for Technegas

2006
Cyclopharm Incorporated and listed on the ASX in 2007

2009
Cyclopharm enters molecular imaging market & establishes MMI imaging JV

2014
Closure of cyclotron production facility and litigation with ANSTO concluded

2015
Cyclopharm signs agreement with DraxImage to commercialise Technegas in the USA

cyclopharm
cyclomedica Nuclear Medicine
cyclopet Nuclear Medicine
MMI Macquarie Medical Imaging
ultralute
Jubilant DraxImage

Cyclopharm
Our Business

cyclopharm Nuclear Medicine

cyclomedica Nuclear Medicine (Technegas)	Manufacturer and distributor of functional lung ventilation imaging drugs and equipment	Å Continues to generate growing revenue, profits and cash flows Å Trials underway to extend usage to COPD treatment & monitoring Å FDA trials progressing Å Partnership with DraxImage for USA commercialisation
ultralute	Technology which extends the useful life of Mo99 generators by up to 50%	Å Finalised testing in 2014 Å IP Secured Å Launch expected in late 2015
MMI Macquarie Medical Imaging	Joint Venture with Macquarie University Hospital	Å Growth tied to hospital ramp-up Å Now EBIT positive
cyclopet Nuclear Medicine	Cyclotron business (ceased operations in April 2014)	Å Received $2.65m cash from ANSTO/PETNET in 2H 2014 Å Facility's medium to long term status under evaluation

Technegas
Expanding the global footprint

- Technegas sold in 55 countries
  - In 2014 Canada became largest single market for Technegas overtaking France
- Over 3,500,000 patient studies since 1986
- 1,350 Technegas generators sold globally
- FY2014 Technegas sales $11.49M generating an EBITDA of $2.16M, a 10% increase over 2013.
- Increasing market in North America pending simplified clinical trial and approval of United States FDA
- Seeking regulatory approval to commence sales in Russia
- October 2013 received marketing approval in Japan
- Expanding the use of Technegas targeting COPD with trials underway in China
- USA licensing agreement with DraxImage being finalised with primary commercial terms agreed

Technegas Sales Revenue by Region



Technegas

cyclopharm
Nuclear Medicine

- ✓ More accurate and sensitive imaging agent primarily used in Pulmonary Embolism
- ✓ Three parts to the technology: generator, aerosol tubing (Patient Administration Set / “PAS”) and crucible(creates nanoparticles)
- ✓ PAS is a consumable used in every Technegas procedure.
- ✓ Technegas generators used on-site to manufacture Technegas
  - Third generation Technegas Generator under development
- ✓ Sales and marketing initiatives targeting technicians, clinicians and referring physicians (pulmonologists/respirologists)
- ✓ Strong growth in CY2014 sales in Europe +8% , North America +27% and Asia +33% despite global downward pressures for healthcare products
- ✓ Positive pricing trends continue
- ✓ Shift in distribution model in some markets to agents to improve margins and accelerate sales
- ✓ Revenue model based on recurrent sales and ongoing service fees

Nuclear imaging: Technegas' superior performance

cyclopharm Nuclear Medicine

Technegas advantages

- Over 3.5m patient studies without a single adverse patient event
- A superior alternative to CTPA (angiograms) in nuclear medicine imaging
- Better clinical results at a fraction of the high radiation does used in CTPA
- More accurate and sensitive measurement in diagnosing Pulmonary Embolism
- Works well with conditions CTPA is contraindicated …eg renal impairment
- Dry nanoparticle aerosol that mimics a true gas.
- Improved patient comfort with only 3-4 breaths required for delivery
- Allows for 3D images

Competitive Nuclear Medicine products

- Xenon 133, being a true gas patient has to re-breathe gas – patient discomfort, can't provide 3D images
- DTPA, liquid aerosol, coalesces into larger droplets – reduced penetration with inferior images in patients with COPD. Off-label use in the USA
- Generic Barrier to Entry
  - R&D on 2nd generation generators that can only uses Technegas
  - Need all three to capture market share – generator, PAS and service capability

TECHNEGAS OVERVIEW
Agency vs Distributor Models

- The majority of Technegas sales are generated through Distributors
- Technegas is distributed directly in Australia, New Zealand, Canada and Germany
- Distributors allow for low cost market entry at the compromise of full market penetration and control
- From 2015 Cyclopharm is currently piloting an agency program in Japan, China and Benelux
- Agency agreements in place run through the end of 2015 at which time the program will be reviewed

Agency Model:

- CYC controls end-user sell price
- CYC gets to see every customer invoice
- CYC receives the agent's margin
- CYC pays agent's out-of-pocket expenses
- CYC pays the agent a consulting fee
- CYC pays the agent a commission
- CYC owns stock on consignment to distributor

Distributor Model:

- Distributor purchases goods from CYC
- Distributor controls the end-user sell price
- CYC does not see customer invoices
- Margin remains with distributor
- Stock is owned by distributor

Technegas – Clinical Trial Program Overview

cyclopharm Nuclear Medicine

USA – Region Expansion Targeting existing Pulmonary Embolism (PE) market

Structural ventilation study comparing Xe133 vs. Technegas to allow the sale of Technegas in the USA

Market Size:

- Half the world's nuclear medicine departments are in the USA
- USA represents a potential PE market of 480,000 patients per annum. (Current volumes = 200,000 patients per annum)

Timeline:

- Q4 2015- Finalise Clinical trial program
- H1 2016 Stage one trial completed
- H1 2017 Stage two trial completed
- Mid 2017 – USFDA Approval

Study Specifics:

- Patient size: To be determined but the USFDA proposal is targeting <300 patients
- "All Comers" protocol to eliminate previous obstacles in patient recruitment
- Total cost = <$6m will be funded predominantly through the USA partnership with DraxImage

Global – Indication Expansion Targeting Chronic Obstructive Pulmonary Disease (COPD) market

Evaluating the effectiveness of Technegas in early detection of COPD and the presence of the comorbidities associated with the disease

Market Size:

- 30x the size of total PE market
- 65 million people have moderate to severe (COPD).
- Estimates show that COPD becomes by 2030 will be the third leading cause of death worldwide

Timeline:

- Q4 2015 China trial completed
- Q4 2015 Results published and presented at the Asian Pacific Society of Respirology Congress
- Plans to extend COPD initiative to additional markets following China results. Preliminary discussions underway in Canada, South Africa and several European countries

China Study Specifics:

- Patient size: 200 patients
- Total cost = <$400K

USA Existing Market Potential & Licensing Agreement with DraxImage



*VQ- Ventilation Perfusion test is a two part nuclear medicine procedure used to determine the functional relationship between the circulatory system and lungs functional ability to capture oxygen

USA Target Market

- DraxImage is the USA market leader in nuclear medicine lung imaging radiopharmaceuticals
- By teaming with DraxImage more resources can be allocated at capturing CPTA's 85% PE market share
- Cyclopharm with DraxImage is targeting 80% of the $90m ventilation radiopharmaceutical market

DraxImage Licensing Agreement:

- DraxImage to take the lead on USFDA Phase 3 clinical trial Draximage places up to $5.25m at risk for the USFDA clinical trial program with no upfront dilution to existing shareholders
- License agreement will generate 17.5% royalty on sales revenue & 15% margin on COGS
- $2m upfront inventory purchase prior to market launch
- DraxImage converts USFDA trial cost investment into a maximum of 15% equity stake in CYC
- DraxImage to nominate a CYC board position
- CYC holds USA marketing authorisation and maintians global patents
- No impact outside of USA
- Equity and board position subject to USFDA success

Technegas
Indication Expansion – COPD

- The Global incidence of Chronic Obstructive Pulmonary Disease (COPD) is 30x greater than that of Pulmonary Embolism (PE)
- It is estimated that by 2020, C.O.P.D. will be the 4th highest cause of death globally. By 2030 COPD will be the 3rd highest cause of death globally.
- Cyclopharm is undertaking a trial in China to assess the use of Technegas for the diagnosis and management of COPD
  - Preliminary research with Technegas suggests early detection than traditional Spirometry
  - Spirometry- a basic measurement of forced air volume provides no underlying pathophysiology
  - 200 patient trial expected to conclude in late 2015
- Expanding the use of Technegas from Pulmonary Embolism (PE) diagnosis to COPD would represent significant expansion of the market size
  - In China, at any time more than 56.6 million people in China have COPD
  - According to the Lancet 2008, it is predicted that China will see 65 million deaths from COPD and 18 million deaths from lung cancer between 2003 and 2033
- Key drivers of the Chinese COPD market include:
  - China is the greatest producer and user of tobacco in the world*
  - Rapidly Aging Population
  - High use of biomass burning at home for cooking
  - Elevated incidence of post-pulmonary tuberculosis
  - Poor air quality in metropolitan areas



*Fang X et al. Chest 2011; 139: 920-929

Ultralute™

cyclopharm
Nuclear Medicine

Product Overview:

- Cyclopharm patented technology
- Extends the effective life of Mo-99 generator up to 50%
- Each cartridge consumable designed for a maximum of 10 uses
- Patents secured in 2014
- Will be designated as laboratory equipment
- Market introduction represents a base platform for additional applications
- Product launch anticipated in late 2015 with revenues commencing early 2016

Technology features:

- Enables a user to extend the usable life of a Mo99 Generator
- Allows the user to purchase a smaller Mo99 Generator
- Provides greater flexibility in manufacturing products
- Provides a saving of between 30% to 40% in the cost of Tc-99m
- Enhances radiolabelling efficiency and imaging quality
- Purifies contaminants from the Tc99m eluate
- Provides a platform for further product development

ULTRALUTE
Generational Overview

cyclopharm
Nuclear Medicine

GEN 1
- Designed for the end user application
- Ready for launch Q4 2015 with revenues commencing early 2016

GEN 2
- Designed for radiopharmacy application
- Development will commence in 2015 for 2017 launch

GEN 3
- Designed for n,Gamma reactions
- Ultralute technology ideal for concentrating low specific activity generated by n, gamma Mo99 production
- Discussions with Mo99 manufacturers commenced in 2015

Molybdenum Manufacturing and Supply Chain

- There are 4,000 Mo99 generators sold worldwide **each week**.
- 50% are sold to Radiopharmacy with the other 50% are sold directly to end users

Macquarie Medical Imaging

cyclopharm Nuclear Medicine

MMI MACQUARIE MEDICAL IMAGING

- Joint venture with:
  - 50% Alfred Health Solutions
  - 30% Macquarie University
  - 20% Cyclopharm
- Comprehensive suite of imaging modalities
- State of the art research platform
- Growth and profitability linked to ramp-up of Macquarie University Hospital
- Sales revenue increased in 2014 as outpatient initiatives implemented at Macquarie University Hospital
- EBIT Positive as of mid CY 2014

Growth Opportunities and Key Performance Indicators

cyclopharm Nuclear Medicine

Technegas

Currency	< 15% of revenues are $AUD related; Currently > 60 % of Technegas revenues linked to Euro.
Seasonality	Historically 2H revenues are stronger due to higher procedures volume during northern hemisphere winters
Pricing & Product Margins	In 2014 the average selling price for PAS=$49.5 AUD & Technegas Generators = $41.6k AUD. Despite downward pressure on healthcare products globally, Technegas has been able to achieve price increases. Consolidated GM of 76.5% in 2014 made up of PAS, the profitability engine room, accounting for 81.6% of total Technegas revenues.
Sales Volumes	PAS boxes sold in 2014 = 3,784 equating to 189,200 patient studies Technegas generators average 50-60 units per year
Competitive Products	Å Xe133 has been eliminated from the Canadian market with the introduction of Technegas. Xe133 only used in the USA is a $USD 38M product Å Kr89 – excellent imaging properties. Only available in a few countries due to limited availability and high cost Å DTPA in low patient volume sites continue where Technegas is available. Used in the USA off-label Å CTPA continues to dominate the PE space; however concerns with high CTPA radiation dose and improved nuclear medicine imaging techniques are bringing referrers back to nuclear medicine VQ imaging
Intellectual Property	TechnegasPlus generated patented until 2026 A new generation of Technegas generators is under development with the goal to extend patent protection
Clinical Indications	Primarily used for PE. Also used in preplanning and post surgical evaluation for lung resection The incidence of COPD is 30x that of PE. Furthermore, COPD represents an opportunity for ongoing patient mgt
Regional Markets	The USA represents the single largest market with half of the world's nuclear medicine departments located there Existing market for PE in the USA equates to ~460,000 patients per annum
Distribution	Cyclopharm continues to evaluate the effectiveness of Distributors/Agents/Partnerships/Independent
Facility Relocation	After 20 years of tenancy, ANSTO has notified Cyclopharm that our lease will not be renewed. The cost of relocation will have an impact in 2016 with an ongoing increase in facility costs likely.

Growth Opportunities and Key Performance Indicators

cyclopharm
Nuclear Medicine

Ultralute	
Market Penetration	Europe targeted as the primary market to launch due to the highest concentration of end user Mo99 generators in the world 1st Generation targeted for launch in Germany at the EANM in October with initial sales to follow early 2016
Margins	Product launch estimates 50% GM with margin improvement expected from leveraging volume growth
Product Development	1st Generation targeting end users in hospitals and clinics to be launched in 2015 2nd Generations targeted for Radiopharmacy will be introduced in 2017
Other Applications	Discussions underway with interested parties for extended applications with other isotopes
MMI	
Revenue	Volumes closely aligned with the hospital. Continued double digit growth expected per annum in the foreseeable future
Profitability	EBIT positive as of mid CY 2014
MRI Licensing	Significant increase in profitability if Government funded MRI licensing is achieved
Cyclopet	
Molecular Imaging	Following competition for government owned enterprises, Cyclopharm's Board decided to cease commercial operations. Subsequent to this decision the company successfully mediated an outcome that resulted in ANSTO paying $2.65M to Cyclopharm. Cyclopharm has no immediate intention of reentering this market under the current competitive landscape.
Facility	Fully written off. Discussions underway relating to the long term to include disposal of the facility

2015 & Outlook

cyclopharm
Nuclear Medicine

Solid growth prospects and healthy capital position

- ✓ Leveraging off record financial results in 2014
- ✓ Softer Year on Year 2015 1H results due to timing differences in purchases
- ✓ Underlying profitability expected to continue with stronger 2H 2015 confirmed with significant end of year orders received
- ✓ Technegas organic revenue and earnings growth to continue, driven by:
  - Emergence of Canada as largest single market
  - Improved demand and pricing in Europe and China
  - Education program focused on referring physicians commenced
- ✓ USFDA trial development underway
  - Pursuing options to accelerate commercialisation timetable
  - USA partnership secured with Jubilant DraxImage
- ✓ Developing additional Technegas indications to include COPD
- ✓ Targeting first Ultralute™ revenue in early 2016
- ✓ Balance sheet strong
- ✓ Maiden fully franked interim dividend of 0.5c per share to be issued on 14 October 2015

Disclaimer

Certain views expressed here contain information derived from publicly available sources that have not been independently verified.

The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of Cyclopharm Limited and as to the markets for the Company's products. Such statements, estimates and projections reflect various assumptions made by the directors concerning anticipated results, which assumptions may or may not prove to be correct. Cyclopharm Limited has not sought independent verification of the information in this presentation. While the directors believe they have reasonable grounds for each of the statements, estimates and projections and all care has been taken in their preparation, no representation or warranty, express or implied, is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of statements, estimates and projections contained in this presentation. Such statements, estimates and projections are by their nature subject to significant uncertainties, contingencies and assumptions.

To the maximum extent permitted by law, none of Cyclopharm Limited, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of information contained in this presentation.

All references to dollars unless otherwise specified are to Australian dollars.

cyclopharm
Nuclear Medicine

APPENDIX SECTION

FY14 Financial Highlights

cyclopharm
Nuclear Medicine

- ✓ Record sales of $12.1 million
- ✓ Record Technegas division operating EBITDA of $2.2 million
- ✓ Record NPAT of $4.1 million (vs 2013 loss of $10.1m), includes:
  - Technegas division NPAT: $2.4 million; and
  - Net litigation proceeds of $2.2 million
- ✓ Technegas division operating expenses down 5.3% vs 2013 leveraging off implemented cost containment program
- ✓ Cashflow from operations of $4.5 million
- ✓ NAB debt fully repaid with net cash of $3.3 million at year end

FY14 Operating Highlights

cyclopharm
Nuclear Medicine

- ✓ Technegas' sales revenue grew in all major markets
  - Sales of Technegas Generators & Patient Administration Sets up 10% on pcp
  - Canada now represents our no.1 market
- ✓ Commenced Technegas COPD trials in China
- ✓ Progress in obtaining FDA approval for Technegas in the US market
- ✓ Secured IP protection for high value Ultralute technology
  - Targeting early 2016 sales
- ✓ Resolved Cyclopet matter in our favour
  - Operations ceased in April 2014
  - Cyclotron facility reinstatement fully funded by insurance is currently underway
  - Medium to long term status under evaluation

FY14 Group Profit & Loss

cyclopharm Nuclear Medicine

Record Sales and Profit

- Technegas continues to perform strongly
- Price increases and lower A$ drove improved gross margins
- Costs management initiatives saw cost reductions across almost all major expense categories
- Low tax rate driven by recognition of prior year tax losses and R&D tax offset
- Operating cash flow of $4.5m in line with reported NPAT – assisted by litigation settlement

Year ended 31 December ($000's)	**2014**	**2013**
Underlying Results[1]:		
Revenue	**12,047**	**11,882**
Technegas EBITDA (Excludes FDA costs)	2,638	2,246
Cyclopet EBITDA (FY14 = 4 months ops)	(816)	(1,268)
Underlying EBITDA	**1,822**	**978**
Depreciation and amortisation	(266)	(643)
Underlying EBIT	**1,556**	**335**
Reported EBIT	3,578	(9,994)
Interest	(107)	(270)
Tax (expense)/benefit	595	146
Reported NPAT	4,066	(10,119)
Reported Basic EPS (cents)	7.0	(17. 6)

Underlying Results represent results from Continuing Operations excluding one off items related to discontinued Cyclopet business (Litigation settlement and costs + impairment expense), CLSA deposit, FDA expenses and MMI equity accounted earnings. (Net totals: FY14: $2.0m; FY13: -$ 10.3m)

Technegas – FY14 Performance

cyclopharm
Nuclear Medicine

Record financial result

- Technegas recorded a record financial result in FY14
- PAS margins enhanced by improved local prices in Asia and Latin America and forex
- Generator revenue increased from higher volumes and prices offset by lower service revenue
- Strong financial perform supports ongoing investment in R&D and costs associated with expansion into new markets

Year ended 31 December ($000's)	**2014**	**2013**	**Change**
Technegas Results[1]:			
Sales Revenue			
PAS	9,384	8,583	↑ 9.3%
Generators	2,106	1,874	↑ 12.4%
Total Sales	**11,490**	**10,457**	↑ 9.9%
Underlying EBITDA	**2,638**	**2,246**	↑ 17.5%
Underlying EBITDA Margin	*23.0%*	*21.5%*	↑ *1.5%*
FDA Expenses	(478)	(478)	-
EBITDA	2,160	1,767	↑ 22.2%
D&A	(223)	(220)	-
EBIT	**1,937**	**1,547**	↑ 25.2%
EBIT Margin	*16.9%*	*14.8%*	↑ *2.1%*

Underlying Results represent results from Continuing Operations excluding one off items related to discontinued Cyclopet business (Litigation settlement and costs + impairment expense), CLSA deposit, FDA expenses and MMI equity accounted earnings. (Net totals: FY14: $2.0m; FY13: -$ 10.3m)

H1 2015 Group Profit & Loss

cyclopharm Nuclear Medicine

Continued Solid Sales and Profits

- Technegas continues to perform strongly
- Price increases and lower A$ drove improved gross margins
- Costs management initiatives saw cost reductions across almost all major expense categories
- Timing of sales orders to France impacted H1 Revenue.

Half Year ended 30 June ($000's)	**H1 2015**	**H1 2014**
Underlying Results[1]:		
Reported Revenue	**5,078**	**6,554**
Technegas PBT (Excludes FDA costs and PAS sales to France)	526	476
Cyclopet P/(L)BT (2014 = 4 months ops)	(38)	(749)
Underlying PBT	**488**	**(273)**
Reported PBT	285	756
Tax (expense)/benefit	(106)	167
Reported NPAT	179	923
Reported Basic EPS (cents)	0.31	1.61

Underlying Results represent results from Continuing Operations excluding one off items related to discontinued Cyclopet business (Litigation costs), CLSA deposit, FDA expenses and PAS sales to France

H1 2015 Group Balance Sheet

cyclopharm Nuclear Medicine

Balance Sheet Strong with Major Debt Retired

- Improved cash position driven by strong cash flows from operations
- Net proceeds from Cyclopet settlement applied to eliminate NAB debt
- Capacity to fund growth initiatives and ongoing R&D
- Following reinstatement of the Cyclotron facility the medium to long term future of the Cyclopet facility is under consideration to include divestment

Balance as at ($000's)	**30/6/2015**	**31/12/2014**
Cash	3,613	3,268
Other current assets	5,392	5,582
Non-current Assets	2,360	2,111
Total Assets	**11,365**	**10,961**
Current Liabilities	3,348	2,874
Borrowings	214	246
Non-current Liabilities	91	85
Total Liabilities	**3,653**	**3,205**
Net Assets	**7,712**	**7,756**